Generalizability of SPRINT Results to the US Adult Population

被引:123
作者
Bress, Adam P. [1 ]
Tanner, Rikki M. [2 ]
Hess, Rachel [3 ,4 ]
Colantonio, Lisandro D. [2 ]
Shimbo, Daichi [5 ]
Muntner, Paul [2 ]
机构
[1] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA
[3] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT USA
[4] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA
[5] Columbia Univ, Dept Med, New York, NY USA
基金
美国国家卫生研究院;
关键词
control; hypertension; population health; systolic blood pressure; treatment; BLOOD-PRESSURE; SERUM CREATININE; METAANALYSIS; REDUCTION;
D O I
10.1016/j.jacc.2015.10.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In SPRINT (Systolic Blood Pressure Intervention Trial), a systolic blood pressure (SBP) goal of <120 mm Hg resulted in lower cardiovascular disease (CVD) risk compared with an SBP goal of <140 mm Hg. OBJECTIVES The purpose of this study was to estimate the prevalence, number, and characteristics of U.S. adults meeting SPRINT eligibility criteria and determine the broader population to whom SPRINT could be generalized. METHODS We conducted a cross-sectional, population-based study using data from the National Health and Nutrition Examination Survey, 2007 to 2012. The SPRINT inclusion criteria were age >= 50 years, SBP 130 to 180 mm Hg depending on the number of antihypertensive medication classes being taken, and high CVD risk (history of coronary heart disease, estimated glomerular filtration rate of 20 to 59 ml/min/1.73 m(2), 10-year CVD risk >= 15%, or age >= 75 years). Exclusion criteria were diabetes, history of stroke, >1 g in 24 h of proteinuria daily, heart failure, estimated glomerular filtration rate <20 ml/min/1.73 m2, or receiving dialysis. Treated hypertension was defined by self-reported use of medication to lower blood pressure with >= 1 class of antihypertensive medication identified through a pill bottle review. RESULTS Overall, 7.6% (95% confidence interval [CI]: 7.0% to 8.3%) or 16.8 million (95% CI: 15.7 to 17.8 million) U.S. adults, and 16.7% (95% CI: 15.2% to 18.3%) or 8.2 million (95% CI: 7.6 to 8.8 million) adults with treated hypertension met the SPRINT eligibility criteria. Among both the overall U.S. population and adults with treated hypertension, the percentage meeting SPRINT eligibility criteria increased with older age, was higher among males than females, and was higher among non-Hispanic whites compared with non-Hispanic blacks or Hispanics. Of U.S. adults eligible for SPRINT, 51.0% (95% CI: 47.8% to 54.1%) or 8.6 million (95% CI: 8.0 to 9.1 million) were not treated for hypertension. CONCLUSIONS A substantial percentage of U.S. adults meet the eligibility criteria for SPRINT. (C) 2016 by the American College of Cardiology Foundation.
引用
收藏
页码:463 / 472
页数:10
相关论文
共 18 条
  • [1] The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT)
    Ambrosius, Walter T.
    Sink, Kaycee M.
    Foy, Capri G.
    Berlowitz, Dan R.
    Cheung, Alfred K.
    Cushman, William C.
    Fine, Lawrence J.
    Goff, David C., Jr.
    Johnson, Karen C.
    Killeen, Anthony A.
    Lewis, Cora E.
    Oparil, Suzanne
    Reboussin, David M.
    Rocco, Michael V.
    Snyder, Joni K.
    Williamson, Jeff D.
    Wright, Jackson T., Jr.
    Whelton, Paul K.
    [J]. CLINICAL TRIALS, 2014, 11 (05) : 532 - 546
  • [2] [Anonymous], SYST BLOOD PRESS INT
  • [3] *CDCP, NAT HLTH NUTR EX SUR
  • [4] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [5] Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate
    Coresh, J
    Astor, BC
    McQuillan, G
    Kusek, J
    Greene, T
    Van Lente, F
    Levey, AS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (05) : 920 - 929
  • [6] Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
    Cushman, William C.
    Evans, Gregory W.
    Byington, Robert P.
    Goff, David C., Jr.
    Grimm, Richard H., Jr.
    Cutler, Jeffrey A.
    Simons-Morton, Denise G.
    Basile, Jan N.
    Corson, Marshall A.
    Probstfield, Jeffrey L.
    Katz, Lois
    Peterson, Kevin A.
    Friedewald, William T.
    Buse, John B.
    Bigger, J. Thomas
    Gerstein, Hertzel C.
    Ismail-Beigi, Faramarz
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) : 1575 - 1585
  • [7] General cardiovascular risk profile for use in primary care - The Framingham Heart Study
    D'Agostino, Ralph B.
    Vasan, Ramachandran S.
    Pencina, Michael J.
    Wolf, Philip A.
    Cobain, Mark
    Massaro, Joseph M.
    Kannel, William B.
    [J]. CIRCULATION, 2008, 117 (06) : 743 - 753
  • [8] Racial disparities in hypertension prevalence, awareness, and management
    Hertz, RP
    Unger, AN
    Cornell, JA
    Saunders, E
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (18) : 2098 - 2104
  • [9] James PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI 10.1001/jama.2013.284427
  • [10] LaVange L M, 1996, Stat Methods Med Res, V5, P311, DOI 10.1177/096228029600500306